IO Biotech Exceeds Q2 2024 EPS Expectations
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
- Latest
- Trending
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
Aave experiences record $300M liquidation as Ethereum drops, impacting AAVE token. Learn about the effects and market signals.
DC Connected Car raises $2.29 million to enhance AI-powered vehicle diagnostics, revolutionizing auto service and customer experience.
Australian pensions increase investments in disaster insurance due to climate risks and financial stability.
Ubisoft ventures into Ethereum; Ronin suffers hack. Explore key crypto gaming events, updates, and industry shifts.
Clutch Security secures $8.5M funding to enhance its Universal NHI Security Platform addressing AI-driven growth in enterprises.
AI aids first responders by making homes easier to locate, cutting response times.
CSPD employs new VR tech for immersive training, funded by a DOJ grant, enhancing law enforcement skills in 2024.
Rigetti Computing advances 84-qubit tech amid mixed Q2 results.
Pagaya exceeds Q2 earnings, boosts 2024 outlook, citing strong fee revenue growth, strategic alliances, and operational efficiencies.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.